Array Bridge provides products and services that address two important areas in the development of biologics: biosimilar drug comparability analysis and impurity analysis. Array Bridge has developed "antibody arrays" to measure biosimilar drug comparability at the molecular level, providing a measurement of biosimilar conformational comparability. This antibody array-based technology can be used at all stages of biosimilar development, from cell line selection and process development to clinical testing and product release. For impurity analysis, the company provides ELISA kits and reagents for Host Cell Protein quantitation and Western Blot analysis.

Asthmapolis is dedicated to improving the management of asthma for patients and healthcare professionals.  It uses medication sensors, mobile applications, advanced analytics and feedback to help physicians identify those patients who need more help controlling the disease.

Avia Biosystems' products provide solutions to common bottlenecks that limit the development and formulation of biologics. The first product developed by the company, the fluorescence-based Model 2304 Fully Automated Protein Denaturation System, automates protein stability studies, with primary applications in stability testing of protein constructs during discovery and development and biologics formulation stability testing during pre-clinical and clinical development. The system automatically prepares samples and the requested array of buffer and excipient conditions, collects fluorescence data, and processes the data for up to 96 protein samples or formulations.